Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Locally Advanced Gastrointestinal Stromal Tumor
- Locally Advanced Sarcoma
- Metastatic Gastrointestinal Stromal Tumor
- Metastatic Sarcoma
- Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8
- Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
- Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8
- Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
Interventions
- PROCEDURE: Biopsy Procedure
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Computed Tomography
- PROCEDURE: Magnetic Resonance Imaging
- PROCEDURE: Positron Emission Tomography
- DRUG: Rogaratinib
Sponsor
National Cancer Institute (NCI)